1-1 of 1
Paul Batty, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Rituximab, Either As Single Agent or in Combination, Is Superior to Other Treatments in Terms of Response Rate and Progression-Free Survival (PFS) in Patients with Splenic Marginal Zone Lymphoma (SMZL)

Ana Marin-Niebla, MD, Monica Else, MA, MSc, Fatima De la Cruz, MD, Paul Batty, MD, Eduardo Rios-Herranz, MD, Claire E. Dearden, Ildefonso Espigado, MD, PhD, Jose Antonio Pérez Simón, MD, PhD, Daniel Catovsky, MD, Estella Matutes
Journal: Blood
Blood (2011) 118 (21): 4986.
https://doi.org/10.1182/blood.V118.21.4986.4986
Published: 2011